Synaptogenix Inc (SNPX)

[runncoach]

This is a quote from Today's PR. """Bryostatin improved cognition in patients with advanced Alzheimer's disease significantly above their baseline levels in recently completed data analyses that consolidated all pre-specified patients under identical protocol conditions in our two Phase 2 pilot trials," commented Dr. Daniel Alkon, Synaptogenix's President and Chief Scientific Officer. "We believe the results provide evidence of significant AD patient cognitive improvement – with potential clinically meaningful benefit – at a level not observed with the randomized placebo control patients.""

I would like to see the individual data from the previous 2 trials on the 50+ drug treated patients fitting the current trial parameters and the percentage of patients who improved baseline scores. It has to be 85% or more. If course it will be a year+ before we know how much of that could be placebo effect related when we get results of the 6 month trial.